Literature DB >> 31531796

ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?

Daniel W Nelson1, Mark B Faries2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31531796      PMCID： PMC6868333          DOI： 10.1245/s10434-019-07711-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  6 in total

1.  Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis.

Authors:  Daniel W Nelson; Trevan D Fischer; Amanda N Graff-Baker; Ahmed Dehal; Stacey Stern; Anton J Bilchik; Mark B Faries
Journal:  Ann Surg Oncol       Date:  2019-06-10       Impact factor: 5.344

2.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

Authors:  Georgina V Long; Jean-Jacques Grob; Paul Nathan; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Stephen R Lane; Carmen Mak; Philippe Legenne; Keith T Flaherty; Michael A Davies
Journal:  Lancet Oncol       Date:  2016-11-16       Impact factor: 41.316

3.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Authors:  Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry
Journal:  Nature       Date:  2017-04-10       Impact factor: 49.962

4.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

5.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

6.  Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Authors:  Mark B Faries; Nicola Mozzillo; Mohammed Kashani-Sabet; John F Thompson; Mark C Kelley; Ronald C DeConti; Jeffrey E Lee; James F Huth; Jeffrey Wagner; Angus Dalgleish; Daniel Pertschuk; Christopher Nardo; Stacey Stern; Robert Elashoff; Guy Gammon; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2017-10-10       Impact factor: 5.344
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.